LCTX

Business Context and Reporting Period

This summary covers the Form 10-Q filed by BioTime, Inc. (Note: The request metadata listed "Lineage Cell Therapeutics," but the filing text explicitly identifies the registrant as BioTime, Inc.) for the quarterly period ended March 31, 2005. BioTime is a biomedical organization engaged in the research and development of synthetic plasma expanders (Hextend, PentaLyte) and organ preservation solutions (HetaCool). The company generates revenue primarily through licensing fees and royalties from partners such as Hospira (formerly Abbott) and CJ Corp.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 46% to $191,083, driven by a 43% increase in royalty revenue ($165,321 vs. $115,887) due to higher sales of Hextend by Hospira. License fee revenue also rose to $25,762.
• Expense Increases: Total expenses rose to $916,609 from $636,198. Research and Development (R&D) expenses more than doubled to $462,608, primarily due to the initiation of the PentaLyte Phase II clinical trial. General and Administrative (G&A) expenses increased to $454,001.
• Interest Expense Reduction: Net interest expense dropped significantly to $1,064 from $1,137,444 in the prior year. The prior year figure included a one-time charge of approximately $1.1 million related to the extinguishment of debentures in February 2004.
• Liquidity Decline: Cash balances decreased by approximately $659,000 during the quarter, falling from $1.37 million to $711,766.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes existing cash ($711,766) plus anticipated license fees and royalties are sufficient to fund operations through March 31, 2006. The company has implemented a cost-cutting plan, including voluntary salary reductions.
• Product Development:
  • Hextend: Commercially launched; royalties are the primary revenue source. Sales to the U.S. Armed Forces are volatile and difficult to predict.
  • PentaLyte: Phase II clinical trials for hypovolemia in cardiac surgery are underway. Estimated cost is $1 million. FDA approval is required for the pentastarch ingredient.
  • HetaCool: Development for low-temperature surgery is ongoing, supported by a $299,990 NIH grant (approx. $20,160 received to date).
• Key Risks:
  • Capital Needs: The company requires additional equity financing to continue operations and complete clinical trials. Failure to secure funding could force curtailment of operations.
  • Regulatory Approval: Success depends on FDA and foreign regulatory approvals for PentaLyte and HetaCool.
  • Revenue Concentration: Reliance on royalties from Hospira and license fees from CJ Corp.
• Internal Controls: Management identified a significant deficiency in accounting and reporting functions (accounts payable/receivable) but determined it did not rise to the level of a material weakness. An experienced accountant was hired to address this.

Investor Verification Checklist

• Verify the sufficiency of the $711,766 cash balance to fund operations through March 2006, given the high burn rate of clinical trials.
• Confirm the timeline and estimated costs for the PentaLyte Phase II and potential Phase III trials, as these are critical for future revenue.
• Monitor the volatility of U.S. Armed Forces purchases of Hextend, which significantly impacts quarterly royalty revenue.
• Review the status of the co-development agreement for the Japanese market (Hextend/PentaLyte) and the timing of the remaining $150,000 payment due in October 2005.
• Assess the impact of the upcoming adoption of SFAS No. 123R (Share-Based Payment) on future net loss calculations, effective January 1, 2006.